November 05, 2015 – Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, November 5, 2015 — Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 third quarter financial and operating results after the close of U.S. financial markets on Tuesday, November 10, 2015. Xenon management will host a conference call and live audio webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) the same day to discuss the results and to provide a corporate update.
The live call may be accessed by dialing (855) 779-9075 for domestic callers or (631) 485-4866 for international callers, and providing conference ID number 74074102. The webcast will be broadcast live on the investors section of Xenon’s website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics®, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon’s Extreme Genetics® platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech. For more information, please visit www.xenon-pharma.com.
The Xenon logo and “Extreme Genetics” are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.
Chief Financial Officer and Chief Operating Officer
Xenon Pharmaceuticals Inc.
This email message is confidential and may contain privileged information. Any unauthorized dissemination or copying is strictly prohibited. If you have received this message in error, please delete it and notify us (Xenon) immediately.